Luai Al Rabadi, MD
Gastrointestinal Medical Oncology
Luai Al Rabadi, MD
Gastrointestinal Medical OncologyOn this page
About me
Dr. Luai Al Rabadi is a medical oncologist who specializes in caring for patients with cancers of the digestive system.
In his research, Al Rabadi focuses on improving cancer outcomes by studying prevention strategies, new therapies, and trends in how patients receive care. His research aims to provide patients with more effective and personalized treatment options.
Al Rabadi earned his medical degree from the Royal College of Surgeons in Ireland. He completed a residency in internal medicine at MetroHealth Medical Center, an affiliate of Case Western Reserve University. He completed a fellowship in hematology and medical oncology at Oregon Health & Science University.
Outside of work, Al Rabadi enjoys spending time with family, being outdoors, and watching and playing soccer.
Education & training
Board certification
- Medical Oncology, American Board of Internal Med/Medical Oncology
- Hematology, American Board of Internal Medicine/Hematology
- Internal Medicine, American Board of Internal Medicine
Fellowship
- Medical Oncology & Hematology, Oregon Health & Science University - OHSU GME
Residency
- Internal Medicine, MetroHealth Medical Center GME - Case Western
Internship
- Internal Medicine, MetroHealth Medical Center GME - Case Western
Degree
- MD, Royal College of Physicians and Surgeons-Ireland
My expertise
Specialties
Conditions
Locations
Clinical Trials query: q=health_gateway_id_ss%3A%28%224081%22%29+AND+status_s%3A%28%22Recruiting%22%29&rows=4&sort=date_published+desc&fq=content_type%3A%22Clinical+Trial%22
Puiblications query: q=health_gateway_id_ss%3A%28%224081%22%29&rows=4&sort=date_published+desc&fq=content_type%3A%22Publication%22
For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here. The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.